Speaking of manic Monday, in November 2013 Kimberly-Clark, known for products such as Kleenex, announced that it would spin off its health care division into a separate company called Halyard Health.
No need to grab a tissue or eat a tub of ice cream to mourn the breakup on this one. Cramer actually thinks this made a ton of sense.
Additionally, with contagious diseases such as Ebola fresh on the minds of investors, this spin-off came at a good time. Halyard is expected to generate $1.7 billion in annual sales, and is the maker of surgical and infection prevention products for the operating room.
Could the Ebola epidemic really be boosting this stock on its first day of trading? Cramer spoke with Halyard Health CEO Robert Abernathy to find out if it is a distributor within Ebola markets and whether he has seen an increase due to the disease.
"Yes, we are in those markets," Abernathy said. "We manufacture products for infection control that are part of the [Centers for Disease Control] protocol for stopping the advancement of the disease. We are growing a little bit, but it's hard to tell whether it is based on Ebola, or just a normal build up of business due to cold and flu season."
The company's main focus within the first year will be to establish itself independent of Kimberly-Clark, and the second year will be to better utilize their cash surplus to make strategic acquisitions to expand in its markets.
Cramer continued to speculate stocks headed higher, by addressing a few caller favorites in the Lightning Round:
Sysco: "I want that deal closed, it didn't. I'm losing a little heart for SYY. It's just not coming together for me like I thought it would."
Omega Healthcare: "I think that Ventas has got more game, it's got more growth."
Read MoreLightning Round: Celgene, Sysco & more